ATAI
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
17 of 36
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
October 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Investor Presentation
September 2022
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the preparations to initiate the phase comparative study to bridge from to a subcutaneous formulation continue phase study will be completed this year randomized establish human proof of concept | ATAI
Investor Presentation
June 2020
subjects parallel arms of subjects data expected by year end placebo and intravenous primary depression rating scale at hours clinician administered dissociative states scale cadss key safety tolerability running across multiple sites in and the phase comparative study to bridge from to a subcutaneous formulation currently in progress phase study will be completed this year randomized establish human proof of concept | ATAI
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
December 2023
phase study results achieved primary with a safety and tolerability profile comparable to placebo | NeuroSense Therapeutics
BioAtla
Investor Presentation
August 2022
phase study design with | BioAtla
Nuvectis Pharma
Investor Presentation
January 2024
phase a ongoing | Nuvectis Pharma
BioAtla
Investor Presentation
November 2022
phase study design with | BioAtla
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io